Stocks
BioCryst Pharmaceuticals, Inc.BCRX
NASDAQHealthcareBiotechnology$8.22-1.91%
Price as of · delayed, not real-time
Focused on oral and small-molecule medicines for rare diseases, this biopharmaceutical firm is known for its lead drug targeting hereditary angioedema. Investors monitor its pipeline progress and commercialization efforts in niche therapeutic areas.
Market Cap: $1.7B52W Range: $6.00 – $11.31
Congressional Interest in BioCryst Pharmaceuticals, Inc. (BCRX)
3 members of Congress have disclosed 5 trades in BioCryst Pharmaceuticals, Inc. (BCRX), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
5
Unique Politicians
3
Buys
3
Sells
2
Who in Congress Is Trading BCRX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-11-13 | Gilbert Cisneros | buy | $1K – $15K |
| 2023-10-16 | Josh Gottheimer | buy | $1K – $15K |
| 2023-09-15 | Josh Gottheimer | sell | $1K – $15K |
| 2022-08-11 | Josh Gottheimer | buy | $1K – $15K |
| 2018-08-20 | JAMES B. RENACCI | sell | $1K – $15K |